Biolexis Therapeutics, an American Fork-based clinical-stage AI-enabled drug discovery company, has announced the launch of a new subsidiary called Metabolexis, a new pipeline company developing drugs for the treatment of obesity and Type 2 diabetes. The company said the new medications will have the potential to improve human longevity.
“We believe that our novel small molecule therapeutics delivered orally can address some of the toxicity and delivery complications associated with today’s treatments,” said Dr. David J. Bearss, CEO and co-founder of Biolexis Therapeutics. “With the launch of Metabolexis, we have an Please log in to see the rest of this story.
